Yunu

Yunu, Inc. develops a cloud-based clinical trial imaging platform that manages imaging workflow, data and compliance from the initial scan through trial submission. The platform acts as the source data system for trial imaging, unifying reader worklists, structured outputs, automated quality control, protocol-guided measurement and reporting so that radiologists, oncologists and clinical trial coordinators work in one system. It supports more than 30 major imaging response criteria and over 300 trial-specific variants, provides immutable measurement logs and audit trails, real-time QA dashboards, and workflow triggers that automate reader assignment. The company states the platform is not intended for diagnostic use and is limited to research purposes.

For sponsors and CROs, Yunu offers rapid trial setup, automated site data collection, outsourced reads, blinded independent central review (BICR) and central review, real-time dashboards and traceability aligned with ICH E6(R3). For cancer centers and sites, it targets reduced image management effort, unified worklists and access to trained readers, technologists and protocol experts. A related offering, the "Yunuverse," is described as a network giving sponsors and sites on-demand access to credentialed imaging staff, standardized workflows, shared administrative tooling (scheduling, billing, reporting) and broader patient access through additional community sites. A De-ID & Export add-on allows teams to anonymize and export trial images and results within the workflow.

Yunu describes its leadership as experts in medical imaging, AI, research and technology, and lists an advisory group of imaging physicians and researchers including Annick Van den Abbeele, MD, Brad Erickson, MD, Eliot Siegel, MD, Khan Siddiqui, MD, and Mitchel Benovoy. Jeff Sorenson is identified as co-founder and CEO.

Founding story

Yunu was founded in Raleigh, North Carolina, by a team including Jeff Sorenson, who serves as co-founder and CEO. The company frames its origin around the observation that clinical trial imaging data is frequently lost, mismanaged and underutilized, and that clients recognized the problem but lacked a way to solve it; its stated goal is to build communities of imaging-informed researchers to speed development of precision therapies.

Business model

Business-to-business software: clinical trial sponsors, CROs and healthcare institutions gain access to the imaging platform and associated services, with revenue described as coming from subscription agreements tied to ongoing platform access, tiered by users or participating clinical sites, plus additional charges for premium services such as specialized consulting or access to a broader network of trial resources. Yunu also supplies services including trained readers, technologists and protocol expertise.

Subscription-based access to the platform and its tools, tiered by number of users or clinical sites, with added fees for premium services such as consulting or expanded network resources.

Traction

Company materials cite 8,500+ clinical trials running across 8,000+ sites, 400+ life sciences companies using the platform, roughly 2,600–3,000+ users across radiology, oncology and trial roles, and more than 25% of imaging trials on clinicaltrials.gov running on Yunu. The April 2025 funding announcement cited over 5,000 active oncology trials managed for more than 400 pharma sponsors, and coverage at more than 25% of NCI-designated Comprehensive Cancer Centers. Named customer sites include VCU Massey Comprehensive Cancer Center, Huntsman Cancer Institute/University of Utah, and the Medical College of Wisconsin, where a quantitative imaging laboratory reports supporting over 280 clinical trials and response assessments for more than 1,200 patients.

Latest developments

Yunu introduced a De-ID & Export add-on that lets teams anonymize and export trial images and results within the platform workflow, and markets the "Yunuverse" network of imaging staffing, standardized workflows and shared administrative tooling. Following the April 2025 Spring Mountain Capital-led investment, the company is focused on growing its sponsor and site network, releasing additional product features and entering new geographic markets including Asia-Pacific.